Clinical trial
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
NCT00054691 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00054691 |
|---|---|
| Title | ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin |
| Official title | A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Skin Cancer |
| Intervention type | Drug |
| Interventions | Iressa |
| Enrollment | 40 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Feb 7, 2003 |
| Last update posted | Mar 13, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: